Publications by authors named "Aravind Basavapathruni"

Claim this Profile
C
Corrigendum to "Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis" [Anal. Biochem. 416 (2011) 206-210].
Robert A Copeland, Aravind Basavapathruni, Mikel Moyer, Margaret Porter Scott

Anal Biochem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP.
Aravind Basavapathruni, Jodi Gureasko, Margaret Porter Scott, William Hermans, Adarsh Godbole

Biochemistry· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
Nigel J Waters, Scott R Daigle, Bruce N Rehlaender, Aravind Basavapathruni, Carly T Campbell

J Control Release· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Aravind Basavapathruni, Edward J Olhava, Scott R Daigle, Carly A Therkelsen, Lei Jin

Biopharm Drug Dispos· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Aravind Basavapathruni, Lei Jin

Blood· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.
Dongyuan Piao, Aravind Basavapathruni, Pinar Iyidogan, Guangxiu Dai, Wolfgang Hinz

Bioorg Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
Aravind Basavapathruni, Lei Jin, Scott R Daigle, Christina R A Majer, Carly A Therkelsen

Chem Biol Drug Des· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.
Wendy W Yeh, Laura M Brassard, Caroline A Miller, Aravind Basavapathruni, Jinrong Zhang

J Virol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis.
Robert A Copeland, Aravind Basavapathruni, Mikel Moyer, Margaret Porter Scott

Anal Biochem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.
Aravind Basavapathruni, Wendy W Yeh, Rory T Coffey, James B Whitney, Peter T Hraber

J Virol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.
Roger Hunter, Yassir Younis, Clare I Muhanji, Tanith-Lea Curtin, Kevin J Naidoo, Aravind Basavapathruni

Bioorg Med Chem· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reverse transcription of the HIV-1 pandemic.
Aravind Basavapathruni, Karen S Anderson

FASEB J· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of action of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl) thymine as an anti-HIV agent.
Eisuke Murakami, Haiying Bao, Aravind Basavapathruni, Christopher M Bailey, Jinfa Du

Antivir Chem Chemother· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.
Roger Hunter, Clare I Muhanji, Ian Hale, Christopher M Bailey, Aravind Basavapathruni

Bioorg Med Chem Lett· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly.
Aravind Basavapathruni, Karen S Anderson

Curr Pharm Des· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.
Aravind Basavapathruni, Johan Vingerhoets, Marie-Pierre de Béthune, Raymond Chung, Christopher M Bailey

Biochemistry· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
William L Jorgensen, Juliana Ruiz-Caro, Julian Tirado-Rives, Aravind Basavapathruni, Karen S Anderson

Bioorg Med Chem Lett· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Juliana Ruiz-Caro, Aravind Basavapathruni, Joseph T Kim, Christopher M Bailey, Ligong Wang

Bioorg Med Chem Lett· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases.
Eisuke Murakami, Aravind Basavapathruni, William D Bradley, Karen S Anderson

Antiviral Res· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs.
Aravind Basavapathruni, Christopher M Bailey, Karen S Anderson

J Biol Chem· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis.
Adrian S Ray, Eisuke Murakami, Aravind Basavapathruni, Joseph A Vaccaro, Dagny Ulrich

Biochemistry· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase.
Adrian S Ray, Raymond F Schinazi, Eisuke Murakami, Aravind Basavapathruni, Junxing Shi

Antivir Chem Chemother· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.
Adrian S Ray, Aravind Basavapathruni, Karen S Anderson

J Biol Chem· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis